Invicta Diagnostic made an impressive debut on the NSE SME platform on Monday, December 8. The stock opened at ₹100 per share, marking a 17.65% premium over its IPO price of ₹85. Investors tracking SME IPOs in the Indian stock market welcomed the strong listing, reflecting early market interest.
Market Performance
The debut session highlighted robust demand for Invicta Diagnostic shares:
- Listing price: ₹100 per share
- IPO price: ₹85 per share
- Premium on debut: 17.65%
The stock’s initial performance underscores growing attention toward SME IPOs and investors’ confidence in healthcare and diagnostic services.
Main News: IPO Listing
Invicta Diagnostic’s SME IPO successfully concluded its public issue, opening on December 1 and closing on December 3, with allotments finalised on December 4.
- IPO size: ₹28.12 crore (fresh issue)
- Equity shares issued: 33 lakh shares.
- Offer for sale: None.
The proceeds from the IPO will mainly be used to expand operations in Maharashtra, including the establishment of five new diagnostic centres equipped with modern medical technology, while the remaining funds will support general corporate purposes.
The IPO saw strong subscription across investor categories:
- Overall subscription: 4.27x
- Retail portion: 3.44x
- Non-Institutional Investors (NIIs): 6.96x
- Qualified Institutional Buyers (QIBs): 3.51x
The company received bids for 1 crore shares against 23.44 lakh shares on offer, reflecting significant investor interest.
Company Details
Invicta Diagnostic, trading under the brand PC Diagnostics, was established in January 2021 and provides integrated radiology and pathology services. The company operates seven diagnostic centres and a central laboratory across Mumbai, Maharashtra.
- Services offered: Imaging, radiology, teleradiology, and pathology testing
- Geography: Maharashtra, primarily Mumbai
- Brand presence: PC Diagnostics
The company’s focus on comprehensive diagnostic solutions positions it as a growing player in the healthcare SME segment.
Summary
Invicta Diagnostic’s SME IPO debuted at ₹100 per share, marking a strong premium over the ₹85 issue price. The capital raised will support the company in expanding its diagnostic network across Maharashtra and setting up centres with state-of-the-art medical equipment. With a solid presence in Mumbai and expertise in radiology and pathology services, Invicta Diagnostic is set to enhance its footprint in the SME healthcare sector.
Easy & quick
Leave A Comment?